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Abstract 
 
Two main factors that have limited commercialization of (microbial) biosurfactants are firstly 
the limited structural variety, secondly the biological generation of mixtures of molecules in 
combination with batch to batch variation and thirdly the high production price due to low inherent 
productivities, small scale and/or a lack of process knowledge/optimization. 
 
A solution can be offered by applying an integrated bioprocess design (IBD) approach to increase 
uniformity and variety and decrease production costs. Strain generation through genetic 
engineering is followed by thorough production process development (fermentation and 
purification), with feedback coupling to the strain level. Subsequent scale up on one hand enables 
assessing the scalability of the processes and performance of techno-economical and LCA 
analyses, but on the other hand also results in the generation of kg (new) biosurfactants. This 
again enables dedicated application research in a variety of applications. This approach will be 
explained for one of the showcases of biosurfactant production: the yeast Starmerella bombicola, 
more specifically a new strain producing the new and innovative bola sophorolipids (bola SLs). 
 
 
This paper is based on the following book chapter:  
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Maeseneire, S.L., Soetaert, W. 2018. Taking biosurfactants from the lab to the market: hurdles and how to 
take them by applying an integrated process design approach. In: Microbial Biosurfactants and their 
Environmental and Industrial Applications.  I.M. Banat and Thavasi, R.(eds).  CRC Press. “In Press” 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The global surfactant market, worth about 36 billion dollars1 is characterized by hundreds of 
different structural variants, which are found in a wealth of applications, from construction and 
food to precision cleaning industries. About half of this huge production volume is used in 
household and laundry detergents, while the other half is employed in various industries; e.g. 
(oilfield) chemicals, mining, paints and coatings, textile and paper, agrochemicals, industrial 
emulsions, construction, food processing, pharmaceuticals, cosmetics etc. 2. An emerging class 
of surfactants are the so called biosurfactants. Biosurfactants or 100 % biobased surfactants can 
be produced chemically or biologically, starting from natural and renewable building blocks, such 
as sugars and plant oils as substrates, offering a renewable and 100% biobased alternative to 
the traditional (petrochemically produced) surfactants. Bio based surfactants constitute about 3 % 
of the global surfactant market 3, a volume which is mainly dominated by chemically produced 
biosurfactants like MESs, APGs and sugar esters. The biologically produced biosurfactants can 
be obtained through extraction from plants (e.g. cardolite from cashew nut shells), biocatalysis 
(e.g. enzymatic sugar esters) and fermentation (e.g. rhamnolipids, sophorolipids, surfactin and 
xylolipids) better known as microbial biosurfactants. In the latter, biological production process 
(fermentation), natural building blocks, such as sugars and plant oils or even waste/side streams, 
are employed. The ecological advantage associated with such processes, together with the rising 
awareness towards sustainability, clearly underpins the market potential of biosurfactants also 
translated in the patenting activity 4. In this book, the last class of biosurfactants, i.e. microbial 
biosurfactants has been described in detail. Although a lot of research has been devoted to this 
class of biochemicals, a very limited amount is currently available on the market, estimated by 
the authors to account for only a few thousand metric tons/year and thus below 0.1 % of the global 
surfactant market. This limited market penetration is caused by three main reasons: First of all, 
microbial biosurfactants are generally produced as complex mixtures e.g. rhamnolipids can be 
found as mono- and dirhamnolipids and the chain length of the hydrophobic monomers can vary 
5 sophorolipids can be found in acidic and lactonic forms and chain lengths, site of hydroxylation, 
saturations degree etc. 6,7, lipopeptides vary in the constituting amino acids and fatty acids 8,9, 
while MELs vary in their acetylation and acylation degree 10. This situation is schematically 
summarized in Fig. 1, clearly for all the biosurfactants, mixtures are produced, and when one 
speaks about e.g. “sophorolipids”, one is speaking about a mixture of between 20 and 100 
compounds. 
Fig. 1: Schematic representation of the structural variety of biosurfactants (1) 
Rhamnolipids, (2) Mannosylerythritollipids and (3) Sophorolipids. Top: the classic 
representation of the biosurfactants, Below: a schematic representation of the diversity of 
molecular structures captured within the biosurfactant types. 
The fact that mixtures are produced as such is not the biggest issue though. If a mixture does the 
job, the industry and end users will be satisfied, irrespective of it being a mixture. However, the 
fact that the ratio of the respective compounds is prone to variation (culture/growth conditions, 
substrate variation, medium components etc.) 11–16, in combination with the fact that the different 
congeners are often associated with very different properties (e.g. lactonic versus acidic 
sophorolipids 17, MELs with a variation of the ac(et)ylation degree 13,18, RLs with one or two 
rhamnose moieties 19, etc. can result in highly confusing and undesired situations. One batch of 
a specific product can perfectly show completely different functionality as compared to another 
batch of supposedly the same product. The occurrence of such issues is completely unacceptable 
from a market perspective, where products must comply with the specifications defined by the 
manufacturer20. 
A second reason for the small market share, is the fact that the molecular variants of 
microbial biosurfactants, produced at acceptable efficiencies (and thus acceptable production 
costs) by the respective microorganisms, is currently too low as compared with synthetic 
alternatives. In formulation business, mixing and combining ingredients to get to a certain 
functionality, requires the availability of choice. Indeed, a range/a portfolio of hundreds of synthetic 
products is available on the market, while only a handful of microbial biosurfactants is available. 
Last, but not least, price is a major issue. This last issue is a constraint for most new biotech 
products and processes, according to several biotech startups (personal communications). This 
is mostly due to the fact that such new products cannot profit from the economy of scale yet, while 
the associated production processes (strains, fermentation and purification) have not yet been 
thoroughly optimized. Moreover, petrochemical production plants are mostly fully depreciated. To 
summarize the above in three words: uniformity, diversity and efficiency are key issues to resolve 
for increasing the market share of microbial biosurfactants. 
In this paper, the approach followed by researchers at InBio.be and BBEPP to resolve 
these issues and as such bring (new-to-nature) glycolipid biosurfactants to the market, is 
elaborated. In this so-called ‘integrated bioprocess design’ (IBD) approach; strain engineering, 
process development and scale up and dedicated application research are closely interconnected. 
Iteration between the different ‘unit operations’ enables early identification of bottlenecks and the 
definition of solutions along the way. This approach tackles the three bottlenecks mentioned 
above: uniformity, diversity and efficiency. 
 
Increasing molecular variety and uniformity through strain engineering 
The working horse at the core of this ‘IBD’ strategy is the ‘exotic’ yeast Starmerella bombicola 21. 
‘Exotic’, because it is not a well-described lab strain for which molecular tools are readily available, 
like e.g. Saccharomyces cerevisiae. Molecular tools are required for genetic engineering to be 
possible. This first requirement/bottleneck was defined by the research group of Professor 
Soetaert fifteen years ago as the way forward to increase molecular variety and strain efficiency 
(decreasing production costs), while reducing product complexity (increase uniformity). His 
research group, InBio.be, thus set out on the quest to develop such molecular tools for S. 
bombicola, which has resulted in the slow, though eventually exponential expansion of the 
possibilities. A ‘hands on’ overview of this endeavor has been recently compiled 22. The choice for 
this particular yeast strain to be transformed into a platform organism for (new-to-nature 
biosurfactants), is the fact that S. bombicola naturally produces high amounts of the biosurfactant 
sophorolipids (SLs) (> 200 g/L; 4 g/L.h) 23. The biosynthetic pathway of SLs has been elucidated 
by our lab (ref) and the contributing enzymes described and characterized 24–29. 
SLs are a well-known example of glycolipid microbial biosurfactants and are composed of the 
rare disaccharide sophorose, attached to a (hydroxylated) fatty acid chain, and occur in an ‘open’ 
or acidic conformation or ‘closed’ or lactonic conformation (see Fig. 1). S. bombicola, synthesizes 
these molecules in high amounts from renewable resources and even waste streams 15,30–34, 
which results in substantial industrial interest. Commercialization of SLs has thus been pursued 
by several companies, amongst others by Evonik, Soliance and Wheatoleo and application by 
Henkel, Ecover, Saraya, and Wheatoleo 20. SLs are thus one of the microbial biosurfactant 
success stories, being one of the few types that have made it to the market. However, some 
issues are associated with the natural occurring ‘sophorolipids’. As mentioned above, they occur 
as a mixture of lactonic and acidic congeners (see Fig. 1), which have very different properties. 
The ratio of lactonic over acidic, varies between the two extremes and is influenced by media and 
culture conditions 17. Moreover, variation in the acetylation degree of the hydrophilic head group 
24 in the saturation/length of the hydrophobic tail and in its site of hydroxylation (terminal or 
subterminal, and thus linkage to the sophorose head group) occurs. 
Although the biosynthetic enzymes have a certain preference, they are quite promiscuous, 
giving rise to about 20 ‘major’, and no less than over 100 ‘minor’ homologs in the SL mixture. 
Several strategies have been described to at least control the lactonic/acidic ratio, as this variation 
is responsible for the largest part of the functionality shift and in the opinion of the authors, 
explanatory of the varying statements in the literature concerning SLs physicochemical and 
biological characteristics. To give an example, lactonic SLs have clear antimicrobial and -viral 
properties and low foaming potential, while acidic SLs show very low or no antimicrobial activity 
and foam considerably well. Fermentation and purification based strategies can quite efficiently 
generate two types of quite uniform SL types i.e. 1. > 95 % diacetylated lacton SLs and 2. 100 % 
non-acetylated acidic SLs respectively 17,35,36 (see Figs. 1 c and 3) as two structural variants. The 
last are deduced from the first by applying alkaline hydrolysis 37, as such hydrolyzing all ester 
functions (acetyl- and lacton functionalities). Several companies also generate/produce a lactonic 
SL product, which is partly hydrolyzed i.e. generation of a mixture of acidic and lactonic SLs in a 
controlled way. This is done for two reasons: increasing the water solubility of lactonic SLs and 
the stimulation of synergistic effects between the two forms. 
Although the industry has thus eventually managed to valorize the (complicated) potential 
of wild type SLs, genetic engineering offers a more elegant and absolute solution to the 
abovementioned issues. Indeed, the development of a molecular toolkit enabled us (and some 
other research groups) to generate a range of new strains producing (new-to-nature) glycolipids 
(Saerens et al. 2011, 2011b; Roelants et al. 2016; Takahashi et al. 2016; Van Bogaert et al. 2016; 
Van Renterghem et al. 2017). An overview of the most important molecular structures, which can 
be produced at productivities similar as the wild type strain is shown in Fig. 2. 
Fig. 2: Overview of the glycolipid portfolio based on engineered S. bombicola strains for 
the production of new to nature glycolipids at acceptable productivities developed at the 
University of Ghent (InBio.be). Acetylgroups (in blue) can be present (varying degrees) or 
absent. 
In this figure it thus is obvious that we have unchained S. bombicola as a platform organism for 
new types of glycolipid biosurfactants. The availability of a battery of very similar glycolipid 
biosurfactants does not only tackle the ‘diversity’ criterion and proof of concept for other microbial 
biosurfactants. Moreover, this is the first time to our knowledge, that there is a realistic possibility 
to determine in depth structure-function relationships, i.e. investigate the influence of the polar 
head group (one versus two sugars), the influence of acetylation (no, low, medium or high 
acetylation degree), the influence of the functionalization of the lipophilic part, etc. on the 
molecular functionality. Besides these achievements on the first abovementioned key point 
‘diversity, the second bottleneck, ‘uniformity’, was also tackled by our research group. For 
example: a strain was generated which exclusively produces acidic SLs 29 17 and another one 
which exclusively produces lactonic sophorolipids, conditions 17. 
To come back to the abovementioned integrated bioprocess design (IBD) strategy, one of 
the new strains/molecules depicted in Fig. 2, i.e. a new type of SLs, so-called non-symmetrical 
(ns) bolaform SLs, will be used as an example to guide the reader through the several steps of 
this IBD approach. These ns bolaform SLs were quite recently discovered in the wild type SL 
mixture in minute amounts 7. The analytical strength in the early years of SL characterization was 
probably too low to detect these compounds, resulting in their late discovery compared to 
‘sophorolipids’ in general 41,42. In contrast to the structure of classic SLs (i.e. acidic and lactonic 
SLs) (see Figs. 1 c and 3), bolaform SLs consist of two sophorose moieties located on each side 
of the lipophilic chain. Shortly after the discovery of 7, our lab succeeded in generating a strain 
that almost exclusively produces these ns bolaform SLs 39. The term ‘non-symmetrical’ was later 
introduced, because the two sophorose head groups are attached to the lipophilic linker through 
a glycosidic and ester linkage respectively (see Fig. 2). Due to their unique structure, bolaform 
amphiphiles are promising for a range of applications. Synthetic bolaforms are for example 
applied for nanomaterial synthesis of the anti-HIV drug Zidovudine® 43. Bolaform SLs could 
represent an interesting biological alternative and/or addition. Besides such rather high-end 
applications, the use of the bolaform SLs in detergent applications is another possibility as this is 
the market were the major part of industrially produced ‘classic’ SLs find application. After 
pursuing the IBD approach to develop and optimize production methods for these new and 
intriguing molecules (which will be further explained below), it indeed became clear that the 
molecules have a rather limited stability. This was caused by the non-symmetrical nature of the 
molecules, as the ester function is prone to (spontaneous) hydrolysis. This instability complicates 
their production (hydrolysis during fermentation, and more significantly during purification) and 
would give rise to instable functionality in watery applications. Considering the IBD approach, we 
thus thought about ways to circumvent this issue (see Fig. 3). 
 
Fig. 3 Schematic representation of the integrated bioprocess design (IBD) approach 
applied by InBio.be and BBEPP. Strain engineering, process development (fermentation 
and purification) and dedicated application research are closely interconnected and drive 
the movement of the new to nature glycolipids along the innovation chain. 
A solution was identified by coupling back to the strain/fermentation level, aiming to generate 
compounds with two glycosidic linkages (i.e ‘symmetrical’) instead of one glycosidic linkage and 
one ester linkage (i.e. ‘non-symmetrical’) as also depicted in Fig. 2 i.e. symmetrical bola 
sophorosides or disophorosides. A new strain was thus generated which now indeed efficiently 
produces symmetrical bola sophorosides 40. 
As mentioned above, after the development of the non-symmetrical bola SLs producing 
strain, the IBD approach was followed to enable the final valorization of these molecules. First, 
the fermentation to increase efficiency/productivity was investigated, which will be described 
below. In parallel with this, a purification method was developed and thirdly the application 
potential of these new molecules was investigated. Emphasis on the parameter ‘productivity’, as 
the most important parameter influencing efficiency, is used below as this was found to be the 
most important parameter influencing production cost and described in the third part of this 
chapter. 
Increasing efficiency and uniformity through process development 
Both medium composition as feeding regimes and fermentation set up are considered in 
process development. In terms of medium, both the nitrogen source and the choice of the 
hydrophobic carbon source were evaluated and the results of the combined optimization efforts 
are summarized in Table 1. It is clear that all the changes, resulted in a dramatic positive evolution 
of the ns bola SL productivity (i.e. a 14 fold increase).  
Table 1: Summary of the achievements for ns bola SLs productivity along the innovation 
chain for the process development part of the IBD approach. 
 Productivity ns bola SLs (g/L.h) 
CSL + Colza oil 0.05 
YE + Colza oil 0.19 
YE + High oleic sunflower oil (HOSO) 0.22 
YE + Oleic acid 0.44 
YE + Oleic acid + cell retention 0.63 
  
The last result shown in Table 1 is derived from a continuous fermentation, by applying cell 
retention in the stationary phase of the fermentation as schematically depicted in Fig. 4a. Seen 
the high solubility of ns bola SLs (> 500 g/L) and its successful purification using a two-step 
ultrafiltration process 40, the idea arose to couple fermentation and purification in a full continuous 
set up (Fig. 4 a and b). 
Fig. 4: Schematic representation of a full continuous set up for ns bola SLs production i.e. 
fermentation and purification (two step filtration). The continuous fermentation with cell 
retention was successfully performed, but the steady state for constant productivity could 
only be maintained for 10 days. 
Such full continuous set-up would significantly decrease the down-time of the equipment and the 
coupling of fermentation with purification would be a highly innovative achievement for 
biosurfactant production. Although full continuous systems can represent some clear advantages, 
such systems also demand highly robust biosynthesis e.g. constant productivity has to be 
maintained throughout the process. The productivity as shown in Table 3 (0.63 g/L.h) could be 
maintained for 10 days, whereas typically only around 0.37 g/L.h was obtained during fed batch 
fermentations. However, after 10 days of continuous fermentation, the productivity started to drop. 
It was not entirely clear what was the reason for this drop as most of the constituents of the 
medium were fed to the yeasts in the influent. We are currently investigating the cause of the 
productivity drop in detail. Resolving this issue might enable the development of a full continuous 
system as described elsewhere 44. 
Following the IBD approach, in parallel with these fermentation process actions, the strain 
engineering unit operation was also further considered. These strain engineering strategies were 
performed at the University (InBio.be) in parallel with the above described process development 
strategies performed at BBEPP. 
Although the abovementioned accomplishments can be considered as breakthroughs in 
the microbial biosurfactant world, it is clear that to further broaden and optimize the production of 
new to nature glycolipids, in depth metabolic engineering strategies are required. The latter on 
the other hand requires the further expansion of the molecular toolkit and an in-depth knowledge 
of the molecular regulation of SL biosynthesis and its related pathways. The last goals are 
currently thoroughly being investigated at Inbio.be. 
Scale up and techno-economic and environmental profiling 
To further investigate the developed production processes on the techno-economic, but also on 
the environmental level, the developed processes were further scaled up to the 100 L and 15 m³ 
scale. Such scale up not only enabled us to evaluate the feasibility of the processes, but also 
resulted in the generation of kg scale amounts of the product (ns bola SLs) for market exploration 
(see below).  
The technical and economic (TE) feasibility of a dedicated non-symmetrical bola 
sophorolipids (SL) producing plant was subsequently assessed 44. The impact of the fermentation 
productivity (0.05 to 4 g/L.h) and the yearly production scale (0 and 10 kTon per year) on the total 
production cost (CAPEX and OPEX included) is shown in Figure 5. 
 
Fig. 5. Prediction of production costs of ns bola SLs in function of production scale and 
ns bola SL productivity as generated by an in-house developed model (CAPEX and OPEX 
included). The 0.05 g/L.h option was not included to allow clear reading of the figure. The 
plateau for this value was found at around 100 euro/kg. 
45 published a calculated projected production cost of wild type SLs of about 2 euro/kg SLs. 
However, this group assumed very high production volumes (90 000 ton/year). The absolute 
minimum level of production cost will always be dictated by the major substrate cost i.e. glucose 
and oil/fatty acids, together accounting to between 1.5 and 3 euro/kg depending on the used 
substrates. A clear trade-off between cost (substrate, medium, type of DSP) and efficiency would 
have to be considered in detail at a certain production scale. Some parameters will be negligible 
at smaller scale (i.e. CSL versus YE), but might become important at very high scales as such 
parameters do not scale, like labour for example. 
The proposed process and generated data at 15 m³ was also used to calculate the 
environmental impact of the production and use of ns bola SLs similarly as was performed for 
acidic SLs 46. Similarly as described by for acidic SLs by these authors, the environmental impact 
of ns bola SLs was unexpectedly high as compared to classical surfactants. Biosurfactants are 
always considered and described as sustainable and green alternatives to classic surfactants. 
This is a clear illustration of the fact that biobased/green products/processes are not automatically 
the more sustainable solution. However, the largest part (> 87 %) of the environmental impact 
was derived from the use of first generation substrates (glucose and oleic acid) as input for the 
production processes. This impact is derived of the negative influence on the environment of the 
agricultural processes associated with the production of these substrates. 
The use of second generation (2G) substrates or even better, substrates requiring very 
little fertilization/watering (as the 2G substrates are still indirectly associated with these practices 
through the generation of the 1G substrates), would supposedly result in a positive effect on the 
environmental impact if the process efficiencies can remain largely unaffected. The latter was 
thus evaluated at BBEPP using 2G sugars derived from the bio-refinery company CIMV in 
combination with a microbial oil.The results will be described in detail elsewhere, but summarizing: 
this entire (hydrophobic and hydrophilic carbon sources) 2G fermentation for SL production was 
successful and gave rise to good efficiencies and product of excellent quality. Again, further 
optimization of the processes would be required to valorize these results. However, seen the 
outcomes described above, these results were considered as a very positive and innovative result 
as there have not been a lot reports about/of full 2G processes for biosurfactant production. 
Application potential and exploratory marketing 
Depending on the application, the market demands cheap and characterized products offering a 
versatile application range and compatibility with other formulation ingredients. A multitude of 
companies are active in research on/about production and/or application of SLs 20. For the ns 
bola SLs we initially only evaluated their use in ecological detergents as a ‘usual suspect’ 
application. Although quite good results were obtained for such applications 40, the current 
production costs are too high for these types of applications to be a realistic option. When looking 
at Fig. 5, the production cost (not commercial selling price) of ns bola SLs could reach 30 euro/kg 
active matter at the current productivity (~0.7 g/L.h) once about 430 tons of this product would be 
produced/commercialized. We expect that this price should go down for B2C companies to 
‘massively’ apply these compounds in their products. However, as the new molecules have an 
interesting and innovative structure, they might have properties/application potential for more 
high-end applications (e.g. pharma, cosmetics, nanotechnology). However, as the possible 
application potential of the ns bola SLs and with expansion the entire portfolio shown in Fig. 2, is 
very broad, we are currently applying an exploratory strategy considering a very broad variety of 
applications/sectors as shown in Fig. 6. 
 
Fig 6. Representation of the potential application markets for the glycolipid portfolio 
shown in Fig. 3. All of the mentioned markets/applications fields are currently under 
evaluation in partnerships with academia and/or industry. 
The identification of high end applications benefiting from ns bola SLs, would enable their market 
introduction at higher prices, after which the economy of scale will kick in as shown in Fig. 5. This 
third part of the IBD approach is also clearly integrated with the other unit operations. For the ns 
bola SLs for example it became clear during scale up and also during application experiments for 
wash up liquids, that the molecules were not that stable. This subsequently gave rise to the 
development of the strain generating the stable symmetrical bola sophorosides 40. 
After a suitable application is found, the regulatory aspects still have to be taken into 
account, which will be different depending on the targeted application (e.g. food versus 
detergents). Taking this hurdle will be one of the last ones to take before one of the products can 
make it to the market. This regulatory tract is both very laborious and expensive. 
Final thoughts 
The abovementioned accomplishments clearly show that applying an IBD approach can enable 
the valorization of new to nature glycolipid biosurfactants. The unique combination of 
genetic/metabolic engineering strategies, process development, scale-up and application 
development is key to valorize the abovementioned technology platform. 
Although the abovementioned accomplishments can thus be considered as very valuable 
proof of concepts in the microbial biosurfactant world, it is clear that there is still room for a lot of 
improvement. First of all, more in-depth metabolic engineering strategies are required to steer the 
engineering efforts in a rationalized fashion. The latter on the other hand requires the further 
expansion of the molecular toolkit, in-depth knowledge of the molecular regulation of glycolipid 
biosynthesis and its related pathways. The last goals are currently thoroughly being investigated 
at Inbio.be. 
The medium composition is another uncultivated source of improvement. Although we 
have already performed some improvements as described in this chapter, we have not thoroughly 
dissected the medium optimization option yet. This is another point where we are currently 
extensively investing efforts by applying DOE and HTP set-ups. All the above-mentioned efforts 
were performed aiming to reduce the production costs. However, anno 2017 a balance with the 
environmental profile of the molecules should also be considered. In this research it was shown 
that the environmental impact can be drastically decreased by the application of 2G (like) 
substrates. However, these technologies should first be further optimized, to reach similar 
efficiencies and cost as 1G substrates. A last and very important factor is the further and expanded 
exploratory marketing research. First, the determination of basic parameters used to score 
surfactants/glycolipids in a multitude of sectors/applications will aid the substantiated choice for 
more in depth, specific application research. 
To conclude we confirm that applying an integrated bioprocess design strategy (IBPD), i.e. 
considering the entire innovation chain, from genetic engineering through fermentation and 
downstream processing to final application testing, is key to develop new strains and processes 
for the industrial production and commercialization of new biosurfactants and with expansion 
other types of (non-drop in) biochemicals. 
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